Literature DB >> 14986247

Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem.

Dale N Gerding.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14986247     DOI： 10.1086/382084

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  50 in total

1.  The Role of the Intestinal Tract As a Source for Transmission of Nosocomial Pathogens.

Authors:  Usha Stiefel; Curtis J Donskey
Journal:  Curr Infect Dis Rep       Date:  2004-12       Impact factor: 3.725

2.  How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?

Authors:  Thomas J Louie
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

3.  Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.

Authors:  Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 4.  Review: Clostridium difficile-associated disorders/diarrhea and Clostridium difficile colitis: the emergence of a more virulent era.

Authors:  Perry Hookman; Jamie S Barkin
Journal:  Dig Dis Sci       Date:  2007-02-16       Impact factor: 3.199

5.  Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts.

Authors:  Trevor D Lawley; Simon Clare; Alan W Walker; David Goulding; Richard A Stabler; Nicholas Croucher; Piero Mastroeni; Paul Scott; Claire Raisen; Lynda Mottram; Neil F Fairweather; Brendan W Wren; Julian Parkhill; Gordon Dougan
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 6.  Antimicrobial Stewardship: A Call to Action for Surgeons.

Authors:  Massimo Sartelli; Therese M Duane; Fausto Catena; Jeffrey M Tessier; Federico Coccolini; Lillian S Kao; Belinda De Simone; Francesco M Labricciosa; Addison K May; Luca Ansaloni; John E Mazuski
Journal:  Surg Infect (Larchmt)       Date:  2016-11-09       Impact factor: 2.150

7.  Impact of an antimicrobial stewardship program on healthcare-associated Clostridium difficile rates at a community-based teaching hospital.

Authors:  Matthew A Moffa; Thomas L Walsh; Amy Tang; Derek N Bremmer
Journal:  J Infect Prev       Date:  2018-05-19

8.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

9.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

10.  Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Authors:  Rosanna Leuzzi; Janice Spencer; Anthony Buckley; Cecilia Brettoni; Manuele Martinelli; Lorenza Tulli; Sara Marchi; Enrico Luzzi; June Irvine; Denise Candlish; Daniele Veggi; Werner Pansegrau; Luigi Fiaschi; Silvana Savino; Erwin Swennen; Osman Cakici; Ernesto Oviedo-Orta; Monica Giraldi; Barbara Baudner; Nunzia D'Urzo; Domenico Maione; Marco Soriani; Rino Rappuoli; Mariagrazia Pizza; Gillian R Douce; Maria Scarselli
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.